The US Food and Drug Administration (FDA) has approved Valeritas' V-Go Disposable Insulin Delivery Device for use with Novo Nordisk's NovoLog for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin.
Valeritas has examined Humalog and NovoLog and found safe for use with the V-Go Disposable Insulin Delivery Device.
The V-Go is small, lightweight, and worn under the patients’ clothing and is not electronic while easy to operate and use.
The V-Go measures just 2.4 x 1.3 x 0.5 inches and weighs approximately 1 ounce when filled with insulin and patients apply a new V-Go to the skin daily for one 24-hour period.
Valeritas CEO Kristine Peterson said with the addition of NovoLog to the V-Go label, they have demonstrated that the two most widely prescribed fast acting insulins in the US can be used safely with the V-Go and thereby have increased healthcare professional and patient insulin options available for use with the V-Go Disposable Insulin Delivery Device.